Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$78.74 -4.33 (-5.22%)

As of 01/17/2025 03:59 PM Eastern

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
1

Buy
7

Based on 8 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 1 has given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for NVO.

Consensus Price Target

$140.20
78.06% Upside

According to the 8 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $140.20. The highest price target for NVO is $160.00, while the lowest price target for NVO is $105.00. The average price target represents a forecasted upside of 78.06% from the current price of $78.74.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

NVO Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$140.20	$150.40	$144.50	$115.00
Forecasted Upside	78.06% Upside	76.94% Upside	24.08% Upside	7.52% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.52
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	78.06% Upside	24,741.16% Upside	12.44% Upside
News Sentiment Rating	Positive News See Recent NVO News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/8/2025	UBS Group 4 of 5 stars	J. Walton Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Buy
1/6/2025	Sanford C. Bernstein 3 of 5 stars	W. Kapadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
12/23/2024	BMO Capital Markets 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$156.00 ➝ $105.00	+23.53%
12/2/2024	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Parkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+49.39%
6/10/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$156.00	+17.58%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$120.00	+13.75%
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:02 PM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Strong Market Position: Novo Nordisk has a significant market capitalization of $384.27 billion, indicating its robust presence in the pharmaceutical industry, which can provide stability and growth potential for investors.
Recent Stock Performance: The current stock price is $85.63, showing a recent increase, which may indicate positive market sentiment and potential for further appreciation.
Institutional Investment: A notable increase in holdings by institutional investors, such as International Assets Investment Management LLC, which raised its position by over 10,000%, suggests strong confidence in the company's future prospects.
Product Development: Novo Nordisk is actively engaged in the research and development of pharmaceutical products, which can lead to innovative treatments and revenue growth, particularly in the diabetes and obesity markets.
Financial Stability: The company maintains a healthy debt-to-equity ratio of 0.43, indicating a balanced approach to financing and lower financial risk, which is attractive to investors looking for stability.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Volatility in Stock Price: The stock has a 52-week high of $148.15 and a low of $81.50, indicating significant price fluctuations that may pose risks for investors seeking stable returns.
Dependence on Product Pipeline: The company's future growth heavily relies on the success of its product pipeline, which can be uncertain and subject to regulatory challenges.
Market Competition: The pharmaceutical industry is highly competitive, and Novo Nordisk faces pressure from other companies developing similar treatments, which could impact its market share and profitability.
Economic Factors: Broader economic conditions, such as changes in healthcare regulations and pricing pressures, could adversely affect Novo Nordisk's financial performance and stock value.
Lower Current Ratio: With a current ratio of 0.94, the company may face challenges in meeting short-term liabilities, which could raise concerns for investors about liquidity and operational efficiency.

NVO Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $140.20, with a high forecast of $160.00 and a low forecast of $105.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There is currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NVO shares.
: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 78.06% based on their 12-month stock forecasts.
: Over the previous 90 days, Novo Nordisk A/S's stock had 3 upgrades by analysts.
: Novo Nordisk A/S has been rated by research analysts at BMO Capital Markets, BNP Paribas, Cantor Fitzgerald, Sanford C. Bernstein, and UBS Group in the past 90 days.
: Analysts like Novo Nordisk A/S more than other "medical" companies. The consensus rating for Novo Nordisk A/S is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:NVO) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target